IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
|Videos|August 13, 2016
Nizar Abdelfattah from UCLA David Geffen School of Medicine: Looking at Potential Impact of Medications on Macular Atrophy
Author(s)Adam Hochron
Doctors treating patients with age-related macular degeneration face a wide range of complications including the potential dosage for anti-VEGF medications. One question is what role these drugs play in macular atrophy.
Advertisement
Doctors treating patients with age-related macular degeneration face a wide range of complications including the potential dosage for anti-VEGF medications. One question is what role these drugs play in macular atrophy.
Nizar Abdelfattah, MD, from the David Geffen School of Medicine at UCLA discussed the results of one such study during the annual meeting of the American Society of Retina Specialists in San Francisco. Abdelfattah said that while they were looking at whether the medication either caused atrophy or affected its progression they were unable to come up with any definitive answers to either question.
Advertisement
Related to this article
Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.
Stephen Seliger, MD, and Michel Chonchol, MD, join Kidney Compass to discuss a pilot trial of empagliflozin in rapidly progressing ADPKD.
In the SCENARIO trial, a 15-week weight-loss program cut recurrent vascular events by 67% in patients with obesity after minor ischemic stroke or TIA.
In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.
Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.
Colin Church, MBBS, PhD, discusses durable 6MWD and NT-proBNP signals in a TPIP open-label extension and what phase 3 needs to show next.
Colin Church, MBBS, PhD, discusses 24-month open-label extension data showing TPIP remains tolerable in patients with PH-ILD, with no new safety signals.
Advertisement
Advertisement
Trending on HCPLive
1
Nalbuphine ER Rapidly Eases IPF Cough Burden, With Phil Molyneaux, MD, PhD
2
Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD
3
Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis
4
HCPLive Five at CHEST 2026
5